SOURCE: VIVUS, Inc.

VIVUS, Inc.

May 14, 2015 07:00 ET

VIVUS Announces Scientific Presentations

MOUNTAIN VIEW, CA--(Marketwired - May 14, 2015) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today announced the following scientific presentations:

Conference
AACE 2015: American Association of Clinical Endocrinologists
24
th Annual Scientific and Clinical Congress
May 13-17, 2015
Music City Convention Center, Nashville, TN

Date/Time
Poster Presentation Date: Friday, May 15, 2015, 9:45am - 11:00am and 12:30pm - 2:00pm CT
Session Location: Exhibit Hall, Hall B, Third Floor of the Music City Convention Center.
Poster Number: 614
Presentation Title
Second Prospective, Pharmacoepidemiologic Database Analysis of Qsymia® (Phentermine and Topiramate Extended-Release) Usage From a Representative US Sample of Patients
Authors: Craig A. Peterson, MS; Xanna Steelman, BA; Santosh T. Varghese, MD
Affiliations: VIVUS, Inc., Mountain View, CA

Conference
ISPOR 2015: International Society for Pharmacoeconomics and Outcomes Research
20th Annual International Meeting
May 16-20, 2015
Philadelphia Marriott Downtown, Philadelphia, PA

Date/Time
Poster Presentation Date: Wednesday, May 20, 2015, 8:30am - 2:45pm ET
Poster Author Discussion Hour: 12:45pm - 1:45pm ET
Session Location: Level 4 Franklin Hall, Philadelphia Marriott Hotel
Poster Number: PSY13
Presentation Title:
Second Prospective, Pharmacoepidemiologic Database Analysis of Phentermine and Topiramate Extended-Release Usage From a Representative US Sample of Older Patients
Authors: Craig A. Peterson, MS; Xanna Steelman, BA; Santosh T. Varghese, MD
Affiliations: VIVUS, Inc., Mountain View, CA

Date/Time
Poster Presentation Date: Wednesday, May 20, 2015 at 8:30AM - 2:45PM
Poster Author Discussion Hour: 12:45pm - 1:45pm ET
Session Location: Level 4 Franklin Hall, Philadelphia Marriott Hotel
Poster Number: PSY32
Presentation Title:
Effect of Weight Loss on Concomitant Medication Costs in Individuals with Metabolic Syndrome Receiving Phentermine/Topiramate Extended-Release
Authors: Scott Kahan, MD, MPHa; Sunil Karnawat, PhDb
Affiliations: aGeorge Washington University, Washington, DC; bVIVUS, Inc., Mountain View, CA

About VIVUS
VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2014 as filed on February 25, 2015 and as amended by the Form 10-K/A filed on April 30, 2015, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.

Contact Information